Answers are grounded in this paper and cite their sources.
Burn injuries remain a major global health challenge, with surgical interventions often requiring blood transfusions due to substantial intraoperative bleeding. Tranexamic acid (TXA), an antifibrinolytic agent, has demonstrated efficacy in reducing perioperative blood loss across various surgical specialties, but evidence in burn surgery remains limited and inconsistent. This systematic review and meta-analysis aimed to evaluate the hemostatic efficacy of TXA in burn patients undergoing surgical procedures. A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) databases from the inception of databases to June 2025. Randomized controlled trials comparing TXA to placebo or no intervention in burn patients undergoing surgical procedures were included. Data extraction focused on intraoperative blood loss, hemoglobin changes, and hematocrit changes. Quality assessment was performed using the Cochrane Risk of Bias 2.0 tool, and meta-analyses were conducted using random-effects models. Four randomized controlled trials encompassing 264 participants were included, with 130 patients receiving TXA and 134 controls. The pooled analysis demonstrated that TXA significantly reduced intraoperative blood loss with a mean difference of -181.60 mL (95% CI: -267.34 to -95.86; p < 0.0001). TXA was also associated with significantly smaller declines in hemoglobin levels compared to controls (mean difference: -1.02 g/dL; 95% CI: -1.39 to -0.65; p < 0.00001). These findings suggest that TXA provides meaningful hemostatic benefits in burn surgery, although larger multicenter trials are needed to validate these results and assess long-term safety outcomes.
No takes yet. Share an insight, caveat, or question.
Lokesh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: